It is, therefore, plausible that the newly proposed epitope (residues 238–244) of MMP14 in this study would be targetable in stage IV ovarian cancer due to an acquired conformation with increased accessibility of the identified epitope and/or greater levels of the protein at the membrane or in the extracellular space. The gene discussed is MMP14; the disease is ovarian cancer.